Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study-Reference-Cited by-同舟云学术

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Published:2021-04 Issue:4 Volume:22 Page:512-524
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kuruvilla John,Ramchandren Radhakrishnan,Santoro Armando,Paszkiewicz-Kozik Ewa,Gasiorowski Robin,Johnson Nathalie A,Fogliatto Laura Maria,Goncalves Iara,de Oliveira Jose S R,Buccheri Valeria,Perini Guilherme F,Goldschmidt Neta,Kriachok Iryna,Dickinson Michael,Komarnicki Mieczyslaw,McDonald Andrew,Ozcan Muhit,Sekiguchi Naohiro,Zhu Ying,Nahar Akash,Marinello Patricia,Zinzani Pier Luigi

Funder

Merck

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial;Fermé;J Clin Oncol,2002

2. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma;Goodman;J Clin Oncol,2008

3. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

4. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma;Santoro;Blood Adv,2020

5. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma;Puig;Haematologica,2010

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-10

2. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

3. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

4. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

5. Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-09